FGFR2 and cholangiocarcinoma: Infigratinib received FDA approval following the results of a phase II clinical trial (NCT02150967) of 122 patients that demonstrated a 23.1% objective response rate (ORR) in treatment-resistant CCA patients with FGFR2 fusions or rearrangements [138].